Search results
Results from the WOW.Com Content Network
Dextromethorphan, sold under the brand name Robitussin among others, is a cough suppressant used in many cough and cold medicines. [6] In 2022, the US Food and Drug Administration (FDA) approved the combination dextromethorphan/bupropion to serve as a rapid-acting antidepressant in people with major depressive disorder.
Dextromethorphan's effects have been divided into four plateaus. [14] The first plateau (1.5 to 2.5 mg per kg body weight) is described as having euphoria, auditory changes, mild stimulation, and change in perception of gravity. The second plateau (2.5 to 7.5 mg/kg) causes intense euphoria, vivid imagination, and closed-eye hallucinations.
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), is the 2013 update to the Diagnostic and Statistical Manual of Mental Disorders, the taxonomic and diagnostic tool published by the American Psychiatric Association (APA). In 2022, a revised version was published. [1]
In Study 1 (GEMINI), a 6-week randomized controlled trial of dextromethorphan/bupropion versus placebo in people with major depressive disorder, scores on the Montgomery–Åsberg Depression Rating Scale (MADRS)—a scale with a range of 0 to 60 points—decreased with dextromethorphan/bupropion by 15.9 points from a baseline score of 33.6 ...
The provider of a dextromethorphan containing product must acquire proof of age if they believe that the potential purchaser is below the age of 18. Any person found to possess more than one gram of pure dextromethorphan without the required credentials is subject to a $1000 fine for the first offense and a $2500 fine for each subsequent offense.
The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM), the DSM-5, was approved by the Board of Trustees of the APA on December 1, 2012. [80] Published on May 18, 2013, [81] the DSM-5 contains extensively revised diagnoses and, in some cases, broadens diagnostic definitions while narrowing definitions in other ...
On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 (dextromethorphan-bupropion) in Alzheimer's disease agitation. The ...
Similar to the DSM-III-R, the DSM-IV-TR was created to bridge the gap between the DSM-IV and the next major release, then named DSM-V (eventually titled DSM-5). [3] The DSM-IV-TR contains expanded descriptions of disorders. Wordings were clarified and errors were corrected. The categorizations and the diagnostic criteria were largely unchanged.